Tallac Therapeutics selects Dr. Kevin Heller as chief medical officer

Kevin Heller, MD, has been named chief medical officer of Tallac Therapeutics, a biopharmaceutical company using innate and adaptive immunity to fight cancer.

Advertisement

Dr. Heller joins Tallac from Jasper Therapeutics, where he served as executive vice president of research and development. Prior to that, he was the chief medical officer for NextCure, according to a Jan. 19 release.

Dr. Heller got his start in the biopharmaceutical industry at Bristol Myers Squibb, where he eventually became global lead for oncology search and evaluation. He went on to serve as senior medical director for AstraZeneca and vice president and head of antibody clinical development at Incyte.

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Leadership

Advertisement

Comments are closed.